Search
Zongertinib
go.drugbank.com/drugs/DB18762ApprovedInvestigationalZongertinib is a selective, irreversible tyrosine kinase inhibitor that targets human epidermal growth factor receptor 2 (HER2). … [L53873,A274363] On August 8, 2025, the US FDA granted accelerated approval to zongertinib for the treatment of advanced forms of non-small cell lung cancer (NSCLC) with HER2 tyrosine kinase domain
Anti-inhibitor coagulant complex
go.drugbank.com/drugs/DB13151ApprovedInvestigationalIt is used to control bleeding in hemophilia A and B patients with inhibitors. … Anti-inhibitor coagulant complex, also known as FEIBA (factor eight inhibitor bypassing activity), contains several proteins involved in the prothrombinase complex.
Products: FEIBA 500 U, FEIBA 1000 UPapaverine
go.drugbank.com/drugs/DB01113ApprovedInvestigationalIt is a direct-acting smooth muscle relaxant used in the treatment of impotence and as a vasodilator, especially for cerebral vasodilation. … An alkaloid found in opium but not closely related to the other opium alkaloids in its structure or pharmacological actions.
Aceclidine
go.drugbank.com/drugs/DB13262ApprovedAceclidine is a cholinergic muscarinic agonist which began marketing in Europe in the 1970s for the treatment of glaucoma. … [A274283] As compared to less selective miotics, like [pilocarpine], aceclidine's relative stimulation of the ciliary muscle is significantly less and, as such, induces far less myopic shift, lens thickening
Equilin
go.drugbank.com/drugs/DB02187ExperimentalAn estrogenic steroid produced by horses. It has a total of four double bonds in the A- and B-ring. High concentration of equilin is found in the urine of pregnant mares.
Synonyms: 1,3,5,7-Estratetraen-3-ol-17-oneNerandomilast
go.drugbank.com/drugs/DB18237ApprovedInvestigational[L54126] On October 7, 2025, nerandomilast was approved as the first new treatment for idiopathic pulmonary fibrosis in more than a decade. … [L54126] Compared to pan-PDE4 inhibitors, selective PDE4B inhibitors are associated with a lower potential for gastrointestinal adverse events.[A274581] On December 19, 2025, the U.S.
Cefroxadine
go.drugbank.com/drugs/DB11367ApprovedWithdrawnCefroxadine is an orally available cephalosporin antibiotic. As part of its drug class, it shares structural properties to [cefalexin] as well as its activity spectrum.
International brands: Cefthan-DSTrastuzumab emtansine
go.drugbank.com/drugs/DB05773ApprovedInvestigationalSecond that there is a black box warning of serious side effects such as hepatotoxicity, embryo-fetal toxicity, and cardiac toxicity. … Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexPlasminogen
go.drugbank.com/drugs/DB16701ApprovedInvestigational[A236035] This pathway is activated when a clot is no longer needed or to prevent a clot from extending beyond the site of injury. … Plasminogen is a pro-enzyme (i.e. a zymogen) which is cleaved to form plasmin - also known as [fibrinolysin] - as part of the fibrinolytic pathway that breaks down fibrin blood clots.
Sulfisoxazole
go.drugbank.com/drugs/DB00263ApprovedVet approvedA short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms.
Categories: combinations of sulfonamides